---
title: "HEARTSCIENCES INC C/WTS (TO PUR COM) | 10-Q: FY2026 Q2 Revenue: USD 2.419 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/269770340.md"
datetime: "2025-12-15T21:14:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/269770340.md)
  - [en](https://longbridge.com/en/news/269770340.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/269770340.md)
---

# HEARTSCIENCES INC C/WTS (TO PUR COM) | 10-Q: FY2026 Q2 Revenue: USD 2.419 K

Revenue: As of FY2026 Q2, the actual value is USD 2.419 K.

EPS: As of FY2026 Q2, the actual value is USD -0.85.

EBIT: As of FY2026 Q2, the actual value is USD -1.796 M.

### Segment Revenue

-   Revenue for the three months ended October 31, 2025 was $2,419, compared to $0 for the same period in 2024. For the six months ended October 31, 2025, revenue was $4,319, compared to $0 for the same period in 2024.

### Operational Metrics

-   **Net Loss**: The net loss for the three months ended October 31, 2025 was - $2,350,769, compared to - $2,082,918 for the same period in 2024. For the six months ended October 31, 2025, the net loss was - $4,405,763, compared to - $4,134,607 for the same period in 2024.
-   **Gross Margin**: Gross margin for the three months ended October 31, 2025 was $1,411, compared to $0 for the same period in 2024. For the six months ended October 31, 2025, gross margin was $2,551, compared to $0 for the same period in 2024.
-   **Operating Expenses**: Total operating expenses for the three months ended October 31, 2025 were $2,074,814, compared to $1,985,033 for the same period in 2024. For the six months ended October 31, 2025, total operating expenses were $3,950,073, compared to $4,060,700 for the same period in 2024.

### Cash Flow

-   **Operating Cash Flow**: Net cash used in operating activities for the six months ended October 31, 2025 was - $4,287,633, compared to - $4,202,270 for the same period in 2024.
-   **Free Cash Flow**: Not explicitly stated, but net cash provided by financing activities for the six months ended October 31, 2025 was $5,157,222, compared to $2,453,417 for the same period in 2024.

### Unique Metrics

-   **Stock-Based Compensation**: During the six months ended October 31, 2025, the company recognized stock-based compensation for stock options of $611,442, compared to $99,115 for the same period in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to continue investing in research and development to develop technology for new products and aims to launch sales of the MyoVista wavECG, MyoVista Insights, and AI-ECG algorithms or any future potential products into the U.S.
-   **Non-Core Business**: The company is exploring strategic partnerships and raising capital through the sale of additional equity securities or debt to support working capital, continued development, and commercialization of MyoVista Insights, and regulatory clearance of the MyoVista wavECG device and the impaired cardiac relaxation AI-ECG algorithm.

### Related Stocks

- [HSCSW.US](https://longbridge.com/en/quote/HSCSW.US.md)

## Related News & Research

- [Prediction: Vanguard's S&P 500 ETF Will Be Back Above $1 Trillion in Assets Before the Year Is Out. Here's the Math.](https://longbridge.com/en/news/294609950.md)
- [Bitcoin Holders Lose $88,600,000 in Coldcard Crypto Wallet Exploit: Galaxy Researchers](https://longbridge.com/en/news/294653457.md)
- [ROI-OPEC+ oil output hike is irrelevant for now, not for later: Russell](https://longbridge.com/en/news/294620367.md)
- [ANALYSIS-Obesity battle heats up again as Novo claws way back into race with Lilly](https://longbridge.com/en/news/294641770.md)
- [Can Caterpillar (CAT) Justify Its Valuation As AI Data Center Optimism Meets Earnings?](https://longbridge.com/en/news/294635551.md)